Back to Search
Start Over
Total body irradiation + fludarabine compared to busulfan + fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT
- Source :
- Bone Marrow Transplantation, 56(2), 481-491. Nature Publishing Group, Giebel, S, Labopin, M, Sobczyk-Kruszelnicka, M, Stelljes, M, Byrne, J L, Fegueux, N, Beelen, D W, Rovira, M, Spyridonidis, A, Blaise, D, Bornhäuser, M, Karadogan, I, Savani, B N, Nagler, A, Mohty, M & Principal investigators of the contributing institutions 2021, ' Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT ', Bone Marrow Transplantation, vol. 56, no. 2, pp. 481-491 . https://doi.org/10.1038/s41409-020-01050-7, Bone Marrow Transplantation, Bone Marrow Transplantation, 2021, 56 (2), pp.481-491. ⟨10.1038/s41409-020-01050-7⟩
- Publication Year :
- 2021
-
Abstract
- International audience; The optimal conditioning for patients with acute myeloid leukemia in first complete remission treated with allogeneic hematopoietic cell transplantation (allo-HCT) has not been defined so far. In this retrospective study, we compared two "reduced-toxicity" regimens: intravenous busulfan at a total dose of 9.6 mg/kg (3 days) + fludarabine (Bu3/Flu) and total body irradiation at a dose of 8 Gy + fludarabine (TBI8Gy/Flu). In the entire study cohort (n = 518), the probabilities of overall survival (OS), leukemia-free survival (LFS), relapse and non-relapse mortality (NRM) at 2 years for Bu3/Flu and TBI8Gy/Flu were 62% vs. 72.5% (p = 0.051), 59.5% vs. 65% (p = 0.15), 30% vs. 20% (p = 0.01), and 10% vs. 14% (p = 0.18), respectively. In multivariate model for patients
- Subjects :
- medicine.medical_specialty
Transplantation Conditioning
MESH: Busulfan
Medizin
MESH: Graft vs Host Disease
Graft vs Host Disease
[SDV.CAN]Life Sciences [q-bio]/Cancer
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
Busulfan
MESH: Hematopoietic Stem Cell Transplantation
MESH: Transplantation Conditioning
Retrospective Studies
Transplantation
Acute leukemia
MESH: Humans
MESH: Middle Aged
business.industry
Hazard ratio
Hematopoietic Stem Cell Transplantation
Myeloid leukemia
MESH: Retrospective Studies
Retrospective cohort study
Hematology
Middle Aged
Total body irradiation
Fludarabine
Leukemia, Myeloid, Acute
Regimen
030220 oncology & carcinogenesis
MESH: Vidarabine
[SDV.IMM]Life Sciences [q-bio]/Immunology
MESH: Leukemia, Myeloid, Acute
business
MESH: Whole-Body Irradiation
Vidarabine
Whole-Body Irradiation
030215 immunology
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 02683369
- Volume :
- 56
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Bone Marrow Transplantation
- Accession number :
- edsair.doi.dedup.....7a271bda3480115a5c698ba5b59f0ad1